News
GSK, SK to compare COVID-19 vaccine candidate to AZ’s jab
GlaxoSmithKline (GSK) and SK bioscience have launched a Phase III trial of their adjuvanted COVID-19 vaccine candidate, which is set to compare the jab to AstraZeneca’s (AZ) vaccine.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
GlaxoSmithKline (GSK) and SK bioscience have launched a Phase III trial of their adjuvanted COVID-19 vaccine candidate, which is set to compare the jab to AstraZeneca’s (AZ) vaccine.